These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23988356)

  • 1. Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity.
    Kojima A; Takita S; Sumiya T; Ochiai K; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Kohno Y
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5311-6. PubMed ID: 23988356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
    Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity.
    Ochiai K; Takita S; Eiraku T; Kojima A; Iwase K; Kishi T; Fukuchi K; Yasue T; Adams DR; Allcock RW; Jiang Z; Kohno Y
    Bioorg Med Chem; 2012 Mar; 20(5):1644-58. PubMed ID: 22336247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.
    Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
    Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
    Allcock RW; Blakli H; Jiang Z; Johnston KA; Morgan KM; Rosair GM; Iwase K; Kohno Y; Adams DR
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3307-12. PubMed ID: 21530250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones.
    Ochiai K; Takita S; Kojima A; Eiraku T; Ando N; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5833-8. PubMed ID: 22884989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
    Kawasaki M; Fusano A; Nigo T; Nakamura S; Ito MN; Teranishi Y; Matsumoto S; Toda H; Nomura N; Sumiyoshi T
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2689-92. PubMed ID: 24794103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
    Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
    Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses.
    Allen SH; Johns BA; Gudmundsson KS; Freeman GA; Boyd FL; Sexton CH; Selleseth DW; Creech KL; Moniri KR
    Bioorg Med Chem; 2006 Feb; 14(4):944-54. PubMed ID: 16213142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.
    El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; ElTahir KE
    Bioorg Med Chem; 2012 May; 20(10):3306-16. PubMed ID: 22516672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines.
    Kumar PM; Kumar KS; Mohakhud PK; Mukkanti K; Kapavarapu R; Parsa KV; Pal M
    Chem Commun (Camb); 2012 Jan; 48(3):431-3. PubMed ID: 22075973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of novel 1,2,3-triazole tagged pyrazolo[3,4-b]pyridine derivatives and their cytotoxic activity.
    Kurumurthy C; Veeraswamy B; Sambasiva Rao P; Santhosh Kumar G; Shanthan Rao P; Loka Reddy V; Venkateswara Rao J; Narsaiah B
    Bioorg Med Chem Lett; 2014 Feb; 24(3):746-9. PubMed ID: 24424132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of pyrazolo[3,4-b]pyridines under microwave irradiation in multi-component reactions and their antitumor and antimicrobial activities - Part 1.
    El-borai MA; Rizk HF; Abd-Aal MF; El-Deeb IY
    Eur J Med Chem; 2012 Feb; 48():92-6. PubMed ID: 22178093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.
    Chowdhury MA; Abdellatif KR; Dong Y; Knaus EE
    Bioorg Med Chem; 2008 Oct; 16(19):8882-8. PubMed ID: 18789699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
    Duplantier AJ; Bachert EL; Cheng JB; Cohan VL; Jenkinson TH; Kraus KG; McKechney MW; Pillar JD; Watson JW
    J Med Chem; 2007 Jan; 50(2):344-9. PubMed ID: 17228876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors.
    Samala G; Devi PB; Nallangi R; Yogeeswari P; Sriram D
    Eur J Med Chem; 2013 Nov; 69():356-64. PubMed ID: 24077526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
    Zhou ZZ; Ge BC; Zhong QP; Huang C; Cheng YF; Yang XM; Wang HT; Xu JP
    Eur J Med Chem; 2016 Nov; 124():372-379. PubMed ID: 27597413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
    Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.